Lupus Foundation of America26d
New Study Finds Anifrolumab In Addition to Standard of Care Treatment is Effective at Reducing Organ Damage Accumulation
A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...
Monthly Prescribing Reference27d
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...
pharmaphorum3y
FDA approves AZ's anifrolumab, ending 10-year lupus drug drought
Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back with positive data from a second study – TULIP-2 – that has proved sufficient for the FDA ...
pharmaphorum9d
AZ fleshes out positive trial of revitalised lupus drug anifrolumab
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...
Medical Xpress29d
Drug can stave off organ damage from lupus, research reveals
Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study ...
Tyler Morning Telegraph29d
Drug Can Stave Off Organ Damage From Lupus
Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...